Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. APLS
stocks logo

APLS

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
192.99M
-3.35%
--
--
205.93M
+4.62%
--
--
219.63M
+3.34%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Apellis Pharmaceuticals, Inc. (APLS) for FY2025, with the revenue forecasts being adjusted by -10.72% over the past three months. During the same period, the stock price has changed by 7.99%.
Revenue Estimates for FY2025
Revise Downward
down Image
-10.72%
In Past 3 Month
Stock Price
Go Up
up Image
+7.99%
In Past 3 Month
18 Analyst Rating
up Image0
Wall Street analysts forecast APLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLS is 35.71 USD with a low forecast of 18.00 USD and a high forecast of 60.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
8 Hold
0 Sell
Moderate Buy
up Image0
Current: 19.470
sliders
Low
18.00
Averages
35.71
High
60.00
up Image0
Current: 19.470
sliders
Low
18.00
Averages
35.71
High
60.00
BofA
Neutral
maintain
$23 -> $24
2025-07-16
New
Reason
BofA
Price Target
$23 -> $24
2025-07-16
New
maintain
Neutral
Reason
BofA raised the firm's price target on Apellis to $24 from $23 and keeps a Neutral rating on the shares. Apellis has not provided sales guidance for Syfovre, which would provide more visibility on expectations for the Syfovre launch at this point, the analyst tells investors in a research note.
Morgan Stanley
Equal Weight
maintain
$25 -> $26
2025-07-02
Reason
Morgan Stanley
Price Target
$25 -> $26
2025-07-02
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Apellis to $26 from $25 and keeps an Equal Weight rating on the shares. The royalty purchase agreement with Sobi bolsters Apellis' cash position, the analyst tells investors in a research note.
Wells Fargo
Equal Weight
maintain
$26 -> $29
2025-06-02
Reason
Wells Fargo
Price Target
$26 -> $29
2025-06-02
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Apellis to $29 from $26 and keeps an Equal Weight rating on the shares. The firm thinks Street's early estimates for the pegcetacoplan's launch in C3G/IC-MPGN may be conservative. That said, Wells awaits approval on the June 28 PDUFA and base biz stability before considering getting more constructive.
Wells Fargo
Derek Archila
Equal Weight
maintain
$26 -> $29
2025-06-02
Reason
Wells Fargo
Derek Archila
Price Target
$26 -> $29
2025-06-02
maintain
Equal Weight
Reason
Wells Fargo analyst Derek Archila raised the firm's price target on Apellis to $29 from $26 and keeps an Equal Weight rating on the shares.
Citi
Buy
downgrade
$49 -> $41
2025-05-22
Reason
Citi
Price Target
$49 -> $41
2025-05-22
downgrade
Buy
Reason
Citi lowered the firm's price target on Apellis to $41 from $49 and keeps a Buy rating on the shares following the Q1 report. The firm cut the price target to reflect a more gradual long-term ramp for Syfovre and Empaveli following the earnings report. Citi says its bull thesis is anchored on Empaveli's expected approval on or by July 28. It recommends adding to positions at current share levels.
Mizuho
Neutral
downgrade
$30 -> $20
2025-05-14
Reason
Mizuho
Price Target
$30 -> $20
2025-05-14
downgrade
Neutral
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Apellis Pharmaceuticals Inc (APLS.O) is -16.51, compared to its 5-year average forward P/E of -19.59. For a more detailed relative valuation and DCF analysis to assess Apellis Pharmaceuticals Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-19.59
Current PE
-16.51
Overvalued PE
-0.30
Undervalued PE
-38.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-20.44
Current EV/EBITDA
-25.91
Overvalued EV/EBITDA
104.49
Undervalued EV/EBITDA
-145.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
38.17
Current PS
2.91
Overvalued PS
91.16
Undervalued PS
-14.82

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders areSelling! The selling amount has increased 3426.45% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 132.99% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 3426.45% over the last month.
Sold
Bought

APLS News & Events

Events Timeline

(ET)
2025-07-01
07:04:24
Apellis to receive up to $300M from royalty purchase agreement with Sobi
select
2025-06-06 (ET)
2025-06-06
09:21:58
Apellis, Sobi present data from open-label period of Phase 3 VALIANT study
select
2025-05-07 (ET)
2025-05-07
07:03:23
Apellis expects cash be sufficient to fund operations to profitability
select
Sign Up For More Events
Sign Up For More Events

News

Preview
8.0
07-18NASDAQ.COM
Interesting APLS Put And Call Options For September 19th

  • Put Contract Analysis: The $20.00 put contract for APLS offers a premium of $1.95, allowing investors to potentially purchase shares at an effective cost of $18.05, with a 60% chance of the contract expiring worthless, yielding a 9.75% return on cash commitment.

  • Call Contract Strategy: The $21.00 call contract has a bid of $2.15, providing a potential total return of 13.31% if exercised, with a 46% chance of expiration without exercise, which would still yield a 10.52% additional return for the investor.

Preview
9.0
07-15Newsfilter
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

  • Apellis Pharmaceuticals Presentation: Apellis Pharmaceuticals announced that five abstracts on SYFOVRE® (pegcetacoplan injection) will be presented at the ASRS Annual Scientific Meeting, showcasing its efficacy and safety for treating geographic atrophy due to age-related macular degeneration.

  • Significance of SYFOVRE®: SYFOVRE® is the first approved therapy for geographic atrophy, demonstrating the ability to slow disease progression with as few as six doses per year, offering hope to patients affected by this irreversible condition.

Preview
6.5
07-08MarketWatch
Goldman Sachs lifts S&P 500 forecasts, recommends these three investment moves

  • Market Reaction to Tariff Delays: Investors are uncertain about the implications of postponed tariffs, with concerns about their impact on supply chains, earnings, growth, and inflation.

  • Analyst Warning: Ipek Ozkardeskaya from Swissquote Bank cautions against overly optimistic market sentiments, suggesting that expecting a quick resolution is unrealistic.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Apellis Pharmaceuticals Inc (APLS) stock price today?

The current price of APLS is 19.47 USD — it has decreased -2.84 % in the last trading day.

arrow icon

What is Apellis Pharmaceuticals Inc (APLS)'s business?

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

arrow icon

What is the price predicton of APLS Stock?

Wall Street analysts forecast APLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLS is 35.71 USD with a low forecast of 18.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Apellis Pharmaceuticals Inc (APLS)'s revenue for the last quarter?

Apellis Pharmaceuticals Inc revenue for the last quarter amounts to 166.80M USD, decreased -3.21 % YoY.

arrow icon

What is Apellis Pharmaceuticals Inc (APLS)'s earnings per share (EPS) for the last quarter?

Apellis Pharmaceuticals Inc. EPS for the last quarter amounts to -0.74 USD, increased 37.04 % YoY.

arrow icon

What changes have occurred in the market's expectations for Apellis Pharmaceuticals Inc (APLS)'s fundamentals?

The market is revising Downward the revenue expectations for Apellis Pharmaceuticals, Inc. (APLS) for FY2025, with the revenue forecasts being adjusted by -10.72% over the past three months. During the same period, the stock price has changed by 7.99%.
arrow icon

How many employees does Apellis Pharmaceuticals Inc (APLS). have?

Apellis Pharmaceuticals Inc (APLS) has 705 emplpoyees as of July 19 2025.

arrow icon

What is Apellis Pharmaceuticals Inc (APLS) market cap?

Today APLS has the market capitalization of 2.45B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free